Nucleic Acid Amplification Testing Market: By Technique (Target amplification systems, Probe amplification systems, and Signal amplification), By Application (Infectious Diseases (Viruses, Bacteria, and Others), Cancer, Personalized Medicine, and Genetic and Mitochondrial Disorders), and Geography  

Nucleic Acid Amplification Testing Market size was valued at USD 1,951.4 million in 2022 and is poised to grow at a CAGR of 9.4% from 2023 to 2029. One advantage of signal amplification systems is that they provide more options for target recognition sequences in some circumstances. The increased prevalence of infectious diseases, the rising need for better diagnostic measures, and rising investment in developing new biotechnological diagnostic procedures are driving the Nucleic Acid Amplification Testing market. Furthermore, nucleic acid amplification testing delivers the most exact detection. It is thus frequently preferred over older methods, owing to the growing need for improved testing methods and the biopharmaceutical industry's increased R&D expenditure.  However, the lack of skilled professionals and high costs hampers the nucleic acid amplification testing market. For COVID-19 (SARS-CoV-2), a Nucleic Acid Amplification Test (NAAT) is a form of a viral diagnostic test. NAATs are genetic material detectors (nucleic acids). SARS-CoV-2 NAATs identify the RNA (ribonucleic acid) sequences that make up the virus's genetic material.

Nucleic Acid Amplification Testing Market Key Developments:

In January 2021, Xpert Xpress SARS-CoV-2 of Cepheid was launched for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper respiratory specimens.